The Ozempic Effect: Navigating GLP-1 Receptor Agonists and Oral Health in Modern Dental Practice

GLP-1 receptor agonists are reshaping dental practice across Saudi Arabia. Nearly 1 in 5 overweight adults has used semaglutide — mostly for weight loss, without endocrinological oversight. This evidence-graded review separates pharmacovigilance findings from animal models, presents the bidirectional GLP-1/periodontitis biology, and gives clinicians a protocol built on what the evidence actually supports.

Research

By Dr. Mahmoud H. Al-Johani

Executive Summary

GLP-1 receptor agonists (GLP-1 RAs) — semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro) — have transformed the management of obesity and type 2 diabetes across the Arab world. In Saudi Arabia, nearly 1 in 5 overweight adults has used these medications, and most are taking them primarily for weight loss rather than diabetes control. This creates a large and growing population appearing in dental chairs with drug-related oral manifestations that most clinicians are not yet equipped to recognize or manage.

This review synthesizes the peer-reviewed evidence on the bidirectional relationship between GLP-1 RAs and oral health. It is written with explicit evidence-level labelling — distinguishing human pharmacovigilance data from animal models and in vitro findings — so that clinicians can calibrate their clinical decisions accordingly. A practical management protocol is provided, grounded in what the evidence currently supports.

1. The Saudi Context: Why This Matters Now

Saudi Arabia carries one of the world's heaviest combined burdens of obesity and type 2 diabetes. National data show that 23.1% of adults live with obesity and 23.1% with diabetes — rates that far exceed the global average of 10.5% for diabetes. Projections suggest obesity prevalence may reach 42.9% by 2026.

Into this landscape, GLP-1 RAs have rapidly penetrated. A cross-sectional study from the Eastern Province reported a lifetime prevalence of 18.2% for GLP-1 RA use among overweight and obese adults, with injectable semaglutide commanding 73.9% of the market. Critically, 72.4% of users were taking semaglutide exclusively for weight loss — not under a diabetes diagnosis. This means many GLP-1 patients presenting to dental clinics are not under endocrinological supervision, may not be counselled on oral side effects, and may not connect their dry mouth or new caries to their medication. The dentist becomes a clinical safety net for this group.

The January 2025 SFDA approval of the first generic semaglutide will accelerate access further. This is a permanent shift, not a trend.

2. The Oral Side Effect Profile: What the Evidence Actually Shows

Dry mouth and salivary dysfunction — the strongest signal

The best-quality human evidence for GLP-1 RA oral side effects comes from pharmacovigilance databases. A 2025 analysis of the FDA Adverse Event Reporting System (FAERS) covering 9,746 GLP-1 RA-related reports found that semaglutide generated significant disproportionality signals for dry mouth, dysgeusia, and anosmia, while GERD was a significant signal for all GLP-1 RAs studied (1). (Human pharmacovigilance data; disproportionality analyses cannot establish causality, but signal strength is meaningful.)

A 2025 narrative review examined the mechanistic basis of these findings (2). Semaglutide's prolonged albumin binding leads to sustained GLP-1 receptor activation in salivary gland tissue, potentially causing receptor desensitization, β-arrestin-mediated internalization, and reduced gland responsiveness over time. The review also notes that different GLP-1 RAs engage cAMP and β-arrestin pathways differently — meaning not all agents will carry equal hyposalivation risk. (Mechanistic narrative review; no human RCT data on salivary flow as a primary endpoint.)

The Saudi-affiliated case series by Mawardi et al. was the first to formally document semaglutide-associated hyposalivation in a clinical series, reporting measurable salivary flow reductions with symptom onset linked to dose escalation (3). (Human case series; small sample, no control group.)

An important preclinical counterpoint: an animal study using exendin-4 in an aging rat hyposalivation model found that GLP-1 receptor activation actually improved salivary secretion and preserved gland architecture (4). This biological complexity — with prolonged pharmacological agonism potentially causing desensitization — is not yet resolved and should prevent oversimplification in patient counselling. (Animal model; not directly translatable to human pharmacology.)

GERD and acid erosion — a real, dose-related concern

GI adverse events are among the most consistently documented effects of GLP-1 RAs across human RCTs. The STEP 8 trial reported GI adverse events in 84.1% of semaglutide users and 82.7% of liraglutide users (5). A FAERS-based pharmacovigilance study of 5,442 cases found 45 GI signal types for semaglutide, with GERD among the highest-signal findings (6).

For dentistry, repeated acid exposure causes palatal and posterior occlusal enamel erosion. A systematic review confirmed higher prevalence of dental erosion and caries in GERD patients compared with healthy controls (7). (SR of human studies; direct causal link between GLP-1-induced GERD and dental erosion is inferred, not yet directly demonstrated in a prospective dental study.)

Nutritional depletion and bone metabolism — a plausible concern, not yet established

The potent appetite suppression of high-dose GLP-1 RAs raises legitimate concern about micronutrient adequacy with downstream effects on alveolar bone density and wound healing. A 20-week pilot RCT in older adults (n=20) found no statistically significant differences in whole-body bone mineral density or bone turnover markers between semaglutide and lifestyle-only groups, though the study was underpowered and short-term (8). (Small pilot RCT; insufficient to draw conclusions.)

Clinicians should ask about dietary adequacy and protein intake and consider recommending supplementation, but should not present alveolar bone loss as an established semaglutide complication.

3. The Bidirectional Biology: A Story With Two Directions

How periodontitis undermines GLP-1 drug efficacy

A landmark 2017 study demonstrated that three major periodontal pathogens — Porphyromonas gingivalis, Tannerella forsythia, and Prevotella intermedia — all produce DPP-4-like enzymes capable of cleaving and inactivating GLP-1. Intravenous injection of bacterial DPP-4 in mice significantly lowered active GLP-1 and insulin levels and elevated blood glucose after oral glucose challenge (9). (Animal and in vitro mechanistic study; mechanism is plausible and supported by subsequent work, but human clinical confirmation is still emerging.)

A 2023 Science paper extended this finding to the gut microbiome broadly, showing that microbial DPP-4 can disrupt glucose metabolism in mice with impaired gut barrier function — and that current human DPP-4 inhibitors (gliptins) have little effect on microbial DPP-4 isoforms (10). (Animal and in vitro study; dental implications are plausible but not yet directly tested in human periodontitis patients.)

A 2024 scoping review synthesised this evidence and noted that elevated GLP-1 levels following periodontal treatment have been observed in human studies, supporting the hypothesis that reducing periodontal bacterial load may improve incretin bioavailability (11). (Scoping review; human evidence for this specific effect is observational.)

The clinical implication is compelling even at current evidence levels: treating periodontitis in a GLP-1 RA patient may reduce bacterial DPP-4 activity in the periodontal pocket, preserve drug bioavailability, and support better glycemic control. The dental office becomes a metabolic health intervention site.

How GLP-1 RAs may protect periodontal tissues

A 2020 rat ligature model study found that systemic liraglutide reduced M1 macrophage infiltration, lowered TNF-α and iNOS gene expression in gingiva, and significantly reduced osteoclast numbers and alveolar bone resorption (12). (Animal model; limited translational fidelity.)

A 2020 in vitro and animal study showed that liraglutide inhibited osteoclast formation and bone resorption via suppression of NF-κB and MAPK signalling pathways (13). (Mixed in vitro/animal; mechanistically informative but not clinical.)

A 2025 scoping review examining the full spectrum of bidirectional interactions between periodontitis and GLP-1 pathways concluded that the evidence supports both potential harm of GLP-1 RAs on salivary function and protective effects on periodontal bone and inflammation (14). (Scoping review of mixed evidence.)

The honest summary: GLP-1 RAs have well-grounded mechanistic and preclinical support for periodontal protective effects. Human RCT data with periodontal clinical endpoints — bleeding on probing, probing depth, clinical attachment level — do not yet exist (15). Clinicians should not counsel patients that GLP-1 RAs treat their gum disease; they should frame these as biologically plausible benefits under active investigation.

Peri-implant outcomes — one human retrospective study

A 2021 retrospective cohort study (n=150 at 1 year, n=74 at 2 years) compared peri-implant marginal bone loss in diabetic patients on GLP-1 RAs, insulin, or metformin. GLP-1 RA patients showed significantly less marginal bone loss than both insulin and metformin groups (p<0.01 at both time points) (16). (Human retrospective cohort; significant confounders possible, small sample at 2 years, requires replication.)

This is the only direct human clinical data on GLP-1 RAs and peri-implant bone. It is hypothesis-generating — not yet to be presented to patients as established evidence of implant benefit.

4. Clinical Protocol: Evidence-Informed Practice

Medical history screening — implement immediately

Add the following questions to your standard medical history form:

  • "Are you currently taking any of the following medications?" (list: Ozempic, Wegovy, Mounjaro, Saxenda, Trulicity, Rybelsus)
  • "How long have you been taking it, and what is the current dose?"
  • "Have you experienced dry mouth, changes in saliva, or difficulty swallowing?"
  • "Do you experience nausea, vomiting, or acid reflux?"
  • "Have you noticed a change in your sense of taste?"
  • "Do you have dental implants, or are you planning to have any placed?"

Because 72% of Saudi semaglutide users are taking it for weight loss — not diabetes — standard diabetes-focused medical history questions will miss many of these patients.

Clinical examination — elevated vigilance

For confirmed GLP-1 RA patients, add to your standard examination:

  • Salivary assessment: Unstimulated salivary flow rate (collect into graduated tube for 5 minutes; <0.1 mL/min indicates hyposalivation). Mucosal dryness on mirror drag test.
  • Erosion mapping: BEWE (Basic Erosive Wear Examination) score, with particular attention to palatal surfaces of upper anteriors and posterior occlusal surfaces — classic GERD erosion patterns.
  • Caries risk scoring: Use CAMBRA or equivalent. GLP-1 patients with xerostomia should be re-classified to high risk, regardless of prior history.
  • Periodontal charting: Full-mouth probing with BOP scores. Active periodontitis in a GLP-1 RA patient warrants prompt treatment, both for oral health and for the metabolic reasons described above.
  • Peri-implant probing: If implants are present, document baseline bone levels and probe at each visit.

Preventive interventions — tiered by risk

For all GLP-1 RA patients (foundation tier):

  • Counsel explicitly on the connection between their medication and dry mouth, erosion, and caries risk
  • Recommend increased water intake throughout the day
  • Sugar-free xylitol-containing gum or lozenges as saliva stimulants
  • Soft-bristled toothbrush; wait 30–60 minutes after vomiting or acid reflux before brushing

For patients with confirmed hyposalivation or elevated caries risk:

  • Prescribe 5,000 ppm fluoride toothpaste or custom fluoride trays
  • Carboxymethylcellulose-based saliva substitute gel (nighttime use)
  • MI Paste Plus (CPP-ACP + fluoride) for remineralisation
  • Shortened recall to 3-month intervals
  • Professional fluoride varnish at every recall visit
  • Short-term chlorhexidine 0.12% rinse (2–4 weeks; avoid prolonged use due to staining and microbiome effects)

For patients with GERD or active vomiting:

  • Document acid exposure frequency and type
  • BEWE scoring and longitudinal erosion monitoring
  • Consider glass ionomer or composite coverage of exposed cervical dentin
  • Communicate to prescribing physician if GERD is severe

For implant patients:

  • Increase monitoring frequency and document bone levels at every visit
  • Frame the emerging retrospective data as preliminary, not established

Interprofessional communication

When you detect significant xerostomia, GERD-pattern erosion, or rapid periodontal deterioration in a GLP-1 RA patient, communicate with the prescribing physician:

"Your patient [Name] is taking [drug, dose]. On dental examination, I have identified [finding]. This may be related to their GLP-1 RA use. I have initiated [preventive measure] and will monitor at 3-month intervals. Please review hydration counselling and GI symptom management at your next consultation."

This is consistent with the EFP/WONCA Europe consensus recommending closer collaboration between oral health professionals and family doctors in the management of non-communicable diseases (17).

5. What We Don't Know Yet: Honest Knowledge Gaps

Any clinician reading this field honestly must acknowledge what is missing:

  • No prospective human RCT has measured periodontal clinical endpoints (probing depth, clinical attachment level, BOP) as primary outcomes in GLP-1 RA users vs. controls.
  • Salivary flow has not been measured as a primary endpoint in any human RCT of GLP-1 RAs. All human evidence comes from pharmacovigilance databases and case series.
  • The peri-implant benefit is based on a single retrospective cohort (n=74 at 2 years) and requires prospective replication.
  • Dose-response relationships for oral side effects are not established. It is biologically plausible that the high-dose obesity regimen (semaglutide 2.4 mg weekly) carries a different oral risk profile than the diabetes dose (0.5–1 mg weekly) — but this has not been studied.
  • The protective vs. harmful balance in salivary glands remains mechanistically unresolved. Animal models show GLP-1 receptor activation can restore salivary flow; human pharmacovigilance shows dry mouth signals. These may reflect dose, duration, or receptor desensitisation differences.

These gaps represent major research opportunities for dental researchers in Saudi Arabia and the wider GCC region.

References

  1. Huang RS et al. Otolaryngologic side effects of GLP-1 receptor agonists. Laryngoscope. 2025;135(6):2291-2298. doi:10.1002/lary.31909
  2. Barać M, Roganović J. GLP-1 receptor signaling and oral dysfunction: a narrative review on the mechanistic basis of semaglutide-related oral adverse effects. Biology (Basel). 2025;14(12):1650. doi:10.3390/biology14121650
  3. Mawardi HH et al. Semaglutide-associated hyposalivation: a report of case series. Medicine (Baltimore). 2023;102(52):e36649. doi:10.1097/MD.0000000000036649 **
  4. Jung JE et al. Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4. Eur J Pharmacol. 2025;1011:178445. doi:10.1016/j.ejphar.2025.178445
  5. Wilding JPH et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23620
  6. Husain M et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:940179. doi:10.3389/fpubh.2022.940179
  7. Grainger R et al. Laryngopharyngeal reflux, gastroesophageal reflux and dental disorders: a systematic review. PLoS ONE. 2020;15(4):e0237412. doi:10.1371/journal.pone.0237412
  8. Dinkla L et al. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis. Front Aging. 2025;6:1691007. doi:10.3389/fragi.2025.1691007
  9. Yamanaka W et al. Degradation of incretins and modulation of blood glucose levels by periodontopathic bacterial dipeptidyl peptidase 4. Infect Immun. 2017;85(8):e00277-17. doi:10.1128/IAI.00277-17
  10. Larsen MH et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science. 2023;381(6655):eadd9330. doi:10.1126/science.add9330
  11. Jimenez M et al. Dipeptidyl-peptidase-4 and glucagon-like-peptide-1, a link in the connection between periodontitis and diabetes mellitus — what do we know so far? A scoping review. J Clin Med. 2024;13(3):903. doi:10.3390/jcm13030903
  12. Sawada N et al. Glucagon-like peptide-1 receptor agonist liraglutide ameliorates the development of periodontitis. J Diabetes Res. 2020;2020:8843310. doi:10.1155/2020/8843310
  13. Li Z et al. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R. Biomed Pharmacother. 2020;130:110523. doi:10.1016/j.biopha.2020.110523
  14. Jeong N et al. Periodontitis and GLP-1 pathways: a new frontier in oral-systemic health connections — a scoping review. Front Clin Diabetes Healthc. 2025;6:1679511. doi:10.3389/fcdhc.2025.1679511
  15. Almohammad AA et al. Glucagon-like peptide-1 (GLP-1) receptor agonists in diabetes and obesity: implications for periodontology and family dentistry. Cureus. 2025;17(10):e95792. doi:10.7759/cureus.95792
  16. Huang P et al. Clinical and radiographic variables related to implants with simultaneous grafts among type 2 diabetic patients treated with different hypoglycemic medications: a retrospective study. BMC Oral Health. 2021;21(1):282. doi:10.1186/s12903-021-01576-8
  17. Herrera D et al. Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: consensus report of the joint workshop by the European Federation of Periodontology (EFP) and the European arm of the World Organization of Family Doctors (WONCA Europe). J Clin Periodontol. 2023;50(6):819-841. doi:10.1111/jcpe.13807

Read on SaudiDent